The Chinese Communist Party reached deep into private business and the broader population to drive a recovery, an authoritarian approach that has emboldened its top leader, Xi Jinping.

The order came on the night of Jan. 12, days after a new outbreak of the coronavirus flared in Hebei, a province bordering Beijing. The Chinese government’s plan was bold and blunt: it needed to erect entire towns of prefabricated housing to quarantine people, a project that would start the next morning.

Part of the job fell to Wei Ye, the owner of a construction company, which would build and install 1,300 structures on commandeered farmland.

Everything — the contract, the plans, the orders for materials — was “all fixed in a few hours,” Mr. Wei said, adding that he and his employees worked exhaustively to meet the tight deadline.

“There is pressure, for sure,” he said, but he was “very honored” to do his part.

In the year since the coronavirus began its march around the world, China has done what many other countries would not or could not do. With equal measures of coercion and persuasion, it has mobilized its vast Communist Party apparatus to reach deep into the private sector and the broader population, in what the country’s leader, Xi Jinping, has called a “people’s war” against the pandemic — and won.

China is now reaping long-lasting benefits that few expected when the virus first emerged in the central Chinese city of Wuhan and the leadership seemed as rattled as at any moment since the Tiananmen Square crackdown in 1989.

The success has positioned China well, economically and diplomatically, to push back against the United States and others worried about its seemingly inexorable rise. It has also emboldened Mr. Xi, who has offered China’s experience as a model for others to follow.

While officials in Wuhan initially dithered and obfuscated for fear of political reprisals, the authorities now leap into action at any sign of new infections, if at times with excessive zeal. In Hebei this January, the authorities deployed their well-honed strategy to test millions and isolate entire communities — all with the goal of getting cases, officially only dozens a day in a population of 1.4 billion, back to zero.

The government has poured money into infrastructure projects, its playbook for years, while extending loans and tax relief to support business and avoid pandemic-related layoffs. China, which sputtered at the beginning of last year, is the only major economy that has returned to steady growth.

When it came to developing vaccines, the government offered land, loans and subsidies for new factories to make them, along with fast-tracking approvals. Two Chinese vaccines are in mass production; more are on the way. While the vaccines have shown weaker efficacy rates than those of Western rivals, 24 countries have already signed up for them since the pharmaceutical companies have, at Beijing’s urging, promised to deliver them more quickly.

Other nations, like New Zealand and South Korea, have done well containing the virus without heavy-handed measures that would be politically unacceptable in a democratic system. To China’s leaders, those countries do not compare.

Beijing’s successes in each dimension of the pandemic — medical, diplomatic and economic — have reinforced its conviction that an authoritarian capacity to quickly mobilize people and resources gave China a decisive edge that other major powers like the United States lacked. It is an approach that emphasizes a relentless drive for results and relies on an acquiescent public.

The Communist Party, in this view, must control not only the government and state-owned enterprises, but also private businesses and personal lives, prioritizing the collective good over individual interests.

“They were able to pull together all of the resources of the one-party state,” said Carl Minzner, a professor of Chinese law and politics at Fordham University. “This of course includes both the coercive tools — severe, mandatory mobility restrictions for millions of people — but also highly effective bureaucratic tools that are maybe unique to China.”

In so doing, the Chinese Communist authorities suppressed speech, policed and purged dissenting views and suffocated any notion of individual freedom or mobility — actions that are repugnant and unacceptable in any democratic society.

Among the Communist Party leaders, a sense of vindication is palpable. In the final days of 2020, the seven members of the Politburo Standing Committee, the country’s top political body, gathered in Beijing for the equivalent of an annual performance review, where in theory they can air criticisms of themselves and their colleagues.

Far from even hinting at any shortcomings — the rising global distrust toward China, for example — they exalted the party leadership.

“The present-day world is undergoing a great transformation of the kind not seen for a century,” Mr. Xi told officials at another meeting in January, “but time and momentum are on our side.”

A Party Mobilized

In recent weeks, as new cases kept emerging, the government’s cabinet, the State Council, issued a sweeping new directive. “There cannot be a shred of neglect about the risk of resurgence,” it said.

The dictates reflected the micromanaged nature of China’s political system, where the top leaders have levers to reach down from the corridors of central power to every street and even apartment building.

The State Council ordered provinces and cities to set up 24-hour command centers with officials in charge held responsible for their performance. It called for opening enough quarantine centers not just to house people within 12 hours of a positive test, but also to strictly isolate hundreds of close contacts for each positive case.

Cities with up to five million people should create the capacity to administer a nucleic test to every resident within two days. Cities with more than five million could take three to five days.

The key to this mobilization lies in the party’s ability to tap its vast network of officials, which is woven into every department and agency in every region.

The government can easily redeploy “volunteers” to new hot spots, including more than 4,000 medical workers sent to Hebei after the new outbreak in January. “A Communist Party member goes to the frontline of the people,” said Bai Yan, a 20-year-old university student, who has ambitions to join the party.

Zhou Xiaosen, a party member in a village outside of Shijiazhuang, a city of 11 million people that was among those locked down, said that those deputized could help police violations, but also assist those in need. “If they need to go out to buy medicine or vegetables, we’ll do it for them,” he said.

The government appeals to material interests, as well as to a sense of patriotism, duty and self-sacrifice.

The China Railway 14th Bureau Group, a state-owned contractor helping build the quarantine center near Shijiazhuang, drafted a public vow that its workers would spare no effort. “Don’t haggle over pay, don’t fuss about conditions, don’t fall short even if it’s life or death,” the group said in a letter, signed with red thumb prints of employees.

The network also operates in part through fear. More than 5,000 local party and government officials have been ousted in the last year for failures to contain the coronavirus on their watch. There is little incentive for moderation.

Residents of the northeastern Chinese city of Tonghua recently complained after officials abruptly imposed a lockdown without enough preparations for supplying food and other needs. When a villager near Shijiazhuang tried to escape quarantine to buy a pack of cigarettes, a zealous party chief ordered him tied to a tree.

“Many measures seemed over the top, but as far as they’re concerned it was necessary to go over the top,” said Chen Min, a writer and former Chinese newspaper editor who was in Wuhan throughout its lockdown. “If you didn’t, it wouldn’t produce results.”

The anger has faded over the government’s inaction and duplicity early in the crisis, the consequence of a system that suppresses bad news and criticism. China’s success has largely drowned out dissent from those who would question the party’s central control. The authorities have also reshaped the public narrative by warning and even imprisoning activists who challenged its triumphant version of events.

In the beginning, the pandemic seemed to expose “the fundamental pathologies of Xi-style governance,” said Jude Blanchette, a researcher at the Center for Strategic and International Studies in Washington.

“In fact, with time and hindsight, we see that the system performed in large part as Xi Jinping was hoping it would do,” he added.

The measures in Hebei worked quickly. At the start of February, the province recorded its first day in a month without a new coronavirus infection.

An Economy Revived

In many countries, debates have raged over the balance between protecting public health and keeping the economy running. In China, there is little debate. It did both.

Even in Wuhan last year, where the authorities shuttered virtually everything for 76 days, they allowed major industries to continue operating, including steel plants and semiconductor factories. They have replicated that strategy when smaller outbreaks have occurred, going to extraordinary lengths to help businesses in ways large and small.

China’s experience has underscored the advice that many experts have suggested but few countries have followed: The more quickly you bring the pandemic under control, the more quickly the economy can recover.

While the economic pain was severe early in the crisis, most businesses closed for only a couple of weeks, if at all. Few contracts were canceled. Few workers were laid off, in part because the government strongly discouraged companies from doing so and offered loans and tax relief to help.

“We coordinated progress in pandemic control and economic and social development, giving urgency to restoring life and production,” Mr. Xi said last year.

Zhejiang Huayuan Automotive Parts Company missed only 17 days of production. With the help of regional authorities, the company hired buses to bring back workers, who had scattered for the Lunar New Year holiday and could not return easily since much of the country was locked down at the beginning. Government passes allowed the buses through checkpoints restricting travel.

Workers were only allowed to go back and forth between the factory and dormitories, their temperatures checked frequently. BYD, a large customer, started manufacturing face masks and shipped supplies to Huayuan.

Covid-19 Vaccines ›Answers to Your Vaccine QuestionsAm I eligible for the Covid vaccine in my state?

Currently more than 150 million people — almost half the population — are eligible to be vaccinated. But each state makes the final decision about who goes first. The nation’s 21 million health care workers and three million residents of long-term care facilities were the first to qualify. In mid-January, federal officials urged all states to open up eligibility to everyone 65 and older and to adults of any age with medical conditions that put them at high risk of becoming seriously ill or dying from Covid-19. Adults in the general population are at the back of the line. If federal and state health officials can clear up bottlenecks in vaccine distribution, everyone 16 and older will become eligible as early as this spring or early summer. The vaccine hasn’t been approved in children, although studies are underway. It may be months before a vaccine is available for anyone under the age of 16. Go to your state health website for up-to-date information on vaccination policies in your area

Is the vaccine free?

You should not have to pay anything out of pocket to get the vaccine, although you will be asked for insurance information. If you don’t have insurance, you should still be given the vaccine at no charge. Congress passed legislation this spring that bars insurers from applying any cost sharing, such as a co-payment or deductible. It layered on additional protections barring pharmacies, doctors and hospitals from billing patients, including those who are uninsured. Even so, health experts do worry that patients might stumble into loopholes that leave them vulnerable to surprise bills. This could happen to those who are charged a doctor visit fee along with their vaccine, or Americans who have certain types of health coverage that do not fall under the new rules. If you get your vaccine from a doctor’s office or urgent care clinic, talk to them about potential hidden charges. To be sure you won’t get a surprise bill, the best bet is to get your vaccine at a health department vaccination site or a local pharmacy once the shots become more widely available.

Can I choose which vaccine I get?How long will the vaccine last? Will I need another one next year?

That is to be determined. It’s possible that Covid-19 vaccinations will become an annual event, just like the flu shot. Or it may be that the benefits of the vaccine last longer than a year. We have to wait to see how durable the protection from the vaccines is. To determine this, researchers are going to be tracking vaccinated people to look for “breakthrough cases” — those people who get sick with Covid-19 despite vaccination. That is a sign of weakening protection and will give researchers clues about how long the vaccine lasts. They will also be monitoring levels of antibodies and T cells in the blood of vaccinated people to determine whether and when a booster shot might be needed. It’s conceivable that people may need boosters every few months, once a year or only every few years. It’s just a matter of waiting for the data.

Will my employer require vaccinations?Where can I find out more?

Soon, the company had more orders than it could handle.

An ambulance manufacturer in Anhui Province increased production immediately, buying screws, bolts and other fasteners that Huayuan produces. Then Chinese automakers started needing them as the virus spread and overseas suppliers shut down.

“We just said no to clients who only wanted standard parts — we wanted to sell more specialized parts, with higher profit,” said Chen Xiying, the company’s deputy general manager. “Clients who were slow to pay we rejected outright.”

Like China itself, Huayuan rebounded quickly. By April, it had ordered nearly $10 million of new equipment to start a second, highly automated production line. It plans to add 47 technicians to its work force of 340.

Before the pandemic, multinationals were looking beyond China for their operations, in part prodded by the Trump administration’s trade war with Beijing. The virus itself added to fears about dependence on Chinese supply chains.

The pandemic, though, only reinforced China’s dominance, as the rest of the world struggled to remain open for business.

Last year, China unexpectedly surpassed the United States as a destination for foreign direct investment for the first time, according to the United Nations Conference on Trade and Development. Worldwide, investments plummeted 42 percent, while in China they grew by 4 percent.

“Despite the human cost and disruption, the pandemic in economic terms was a blessing in disguise for China,” said Zhu Ning, deputy dean of the Shanghai Advanced Institute of Finance.

A Diplomatic Tool

Last February, while the coronavirus ravaged Wuhan, one of the country’s biggest vaccine manufacturers, Sinovac Biotech, was in no position to develop a new vaccine to stop it.

The company lacked a high-security lab to conduct the risky research needed. It had no factory that could produce the shots, nor the funds to build one.

So the company’s chief executive, Yin Weidong, reached out to the government for help. On Feb. 27, he met with Cai Qi, a member of China’s Politburo, and Chen Jining, the mayor of Beijing and an environmental scientist.

After that, Sinovac had everything it needed.

The officials gave its researchers access to one of the country’s safest labs. They provided $780,000 and assigned government scientists to help.

They also cleared the way for the construction of a new factory in a district of Beijing. The city donated the land. The Bank of Beijing, in which the municipality is a major shareholder, offered a low-interest $9.2 million loan.

When Sinovac needed fermentation tanks that typically take 18 months to import from abroad, the government ordered another manufacturer to work 24 hours a day to make them instead.

It was the sort of all-of-government approach that Mr. Xi outlined at a Politburo Standing Committee meeting two days after Wuhan was locked down. He urged the country to “accelerate the development of therapeutic drugs and vaccines,” and Beijing broadly showered resources.

CanSino Biologics, a private company, partnered with the People’s Liberation Army, working with little rest to produce the first trial doses by March. Sinopharm, a state-owned pharmaceutical company, got government funding in three and a half days to build a factory.

Mr. Yin of Sinovac called the project “Operation Coronavirus” in keeping with the wartime rhetoric of the country’s fight against the outbreak. “It was only under such comprehensive conditions that our workshop could be put into production,” he told The Beijing News, a state-controlled newspaper.

Less than three months after Mr. Yin’s Feb. 27 meeting, Sinovac had created a vaccine that could be tested in humans and had built a giant factory. It is churning out 400,000 vaccines a day, and hopes to produce as many as one billion this year.

The crash course to vaccinate a nation ultimately opened a different opportunity.

With the coronavirus largely stamped out at home, China could sell more of its vaccines abroad. They “will be made a global public good,” Mr. Xi promised the World Health Assembly last May.

Although officials bristle at the premise, “vaccine diplomacy” has become a tool to assuage some of the anger over China’s missteps, helping shore up its global standing at a time when it has been under pressure from the United States and others.

“This is where China can come in and look like a real savior, like a friend in need,” said Ray Yip, a former head of the Bill and Melinda Gates Foundation in China.

China’s efficiency at home has not translated into an easy triumph abroad. Chinese vaccines have lower efficacy rates. Officials in Brazil and Turkey have complained about delays. Still, many countries that have so far signed up for them have acknowledged that they could not afford to wait months for those made by the Americans or Europeans.

On Jan. 16, Serbia became the first European country to receive Chinese vaccines, some one million doses from Sinopharm. The country’s president, Aleksandr Vučić, stood in chilly winds with the Chinese ambassador to welcome the first planeload of supplies.

He told reporters that he was “not afraid to brag” of the country’s relationship with China.

“I’m proud of that and will invest more and more of our time and efforts to create and even improve our great relationship with the Chinese leadership and the Chinese people.”

Coral Yang, Amber Wang, Claire Fu and Elsie Chen contributed research.



Source link